Increased Transforming Growth Factor-b Levels Associated With Cardiac Adverse Events in XXXX .

@entity1 @entity82 @entity296 @entity943 @entity712 @entity3876 @entity2533 @entity299 @entity123 @entity583 @entity1121
BACKGROUND: @entity1121 ( @entity1121 ) is a common genetic @entity299 characterized by @entity123 , @entity296 , and impaired ventricular relaxation. The exact mechanisms by which @entity82 is caused remain unknown. HYPOTHESIS: Circulating @entity2533 is related to poor prognosis in @entity1121 . METHODS: We compared @entity2533 levels of 49 @entity1121 @entity1 with those of 40 non- @entity1121 @entity1 . We followed the @entity1 with @entity1121 for 18 months and divided them into 2 groups: low @entity2533 ( <=4877 pg/mL) and high @entity2533 (>4877 pg/mL). We compared the 2 groups in terms of @entity3876 ( @entity3876 ), echocardiographic parameters, and clinical outcomes including @entity583 , @entity943 , implantable cardioverter-defibrillator implantation, hospitalization, New York Heart Association (NYHA) class, @entity712 , and mortality. RESULTS: The @entity1121 @entity1 had higher @entity2533 levels than those in the control group (P = 0.005). In the follow-up, those in the high @entity2533 group had higher @entity3876 levels, larger left-atrial size, thicker interventricular septum, NYHA class, more hospitalizations, and a greater number of clinical adverse events (P < 0.001, P = 0.01, P < 0.001, P = 0.002, P < 0.001 and P = 0.003, respectively). @entity2533 level of >4877 pg/mL can predict adverse events with a specificity of 75% and a sensitivity of 72% (P = 0.014). In multivariate regression analysis, @entity2533 , @entity3876 , and interventricular septum thickness were significantly associated with adverse events (P = 0.028, P = 0.030, and P = 0.034, respectively). CONCLUSIONS: The @entity2533 level is higher in @entity1121 @entity1 and associated with a poor prognosis in @entity1121 .
